NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
- Award ceiling
- Not stated
- Closes
- Apr 5, 2027
- Last verified
- 2026-10-22
Per-recipient award not stated for small businesses, closing Apr 5, 2027.
In one sentence
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) does not state a per-recipient award amount, open to small businesses in US, closing Apr 5, 2027.
- Program pool (total)
- Not confirmedTotal across all awards in this programme. Not an amount any single applicant can receive.
- Award ceiling (per project)
- Not confirmed
- Award floor
- Not confirmed
- Typical award
- Not confirmed
- Deadline
- Apr 5, 2027
- Deadline type
- Fixed date
- Opens
- May 28, 2026
- Status
- Open
- Eligible entities
- Small businesses
- Geography
- US
- Matching funds
- No
- Disbursement
- Not confirmed
- Application effort
- Not confirmed
- Use of funds
- feasibility studies · research and development · develop a commercial product
- Currency
- USD
How much money is available?
Two different figures govern a programme and they are not interchangeable. The programme pool is what the funder has allocated across every award it will make this cycle. The award ceiling is the most one applicant can be granted.
Who can apply?
Not confirmed
Source field: applicant size limitOnly United States small business concerns (SBCs), as defined by the Small Business Administration (SBA)(sbir.gov/apply) are eligible to submit applications for this opportunity.Refer to Section III. Eligibility Information in the NOFO…
We store the structured fields above. Clause-by-clause text from the guidelines is not connected for this record.When does it close?
What can the money be used for?
3 categorysThe source’s own spending categories, and what is not parsed.
These categories come from the source's own classification. A line-item cost table, where the programme publishes one, lives in the guidelines and is not parsed for this record.
How hard is the application?
1 fieldEffort, match requirement and reimbursement, as the source stated them.
- Application effort
- Not confirmed
- Disbursement
- Not confirmed
- Matching funds
- No
What comparable notices state
291 recordsStated ceilings on open records in the same industry.
Among open records stored under Health & Human Services, 291 of 889 state an award ceiling. Those that do run:
- 25th percentile$357,500
- Median$600,000
- 75th percentile$1,500,000
A statistical estimate, not a prediction. It describes what a set of notices has published in this catalogue on the day you read it, and says nothing about what this programme will award. Records stating no ceiling are excluded rather than counted as zero, and the programme pool — what a funder has across every applicant — is a different column and is never mixed in.
Who has won this programme before?
131222 awardsAwards under the same assistance listing, not under this notice.
131222 federal awards on file under assistance listing 93.113, 93.121, 93.172, 93.173, 93.213, 93.233, 93.242, 93.273, 93.279, 93.286, 93.307, 93.313, 93.350, 93.351, 93.361, 93.393, 93.394, 93.395, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.879, the programme this notice is published under. These are not awards made under this notice — a listing covers every year the programme runs, and awards under an open notice do not exist yet.
- $1,073,967,938FRED HUTCHINSON CANCER CENTERWA · FY2006
- $973,507,476UNIVERSITY OF CALIFORNIA, LOS ANGELESCA · FY2006
- $719,372,575FAMILY HEALTH INTERNATIONALNC · FY2006
- $463,372,200REGENTS OF THE UNIVERSITY OF MICHIGANMI · FY1998
- $443,702,768FRED HUTCHINSON CANCER CENTERWA · FY2006
Common questions
5 questionsEvery answer is a stored field from this record. Questions the source did not answer are not asked.
- When is the application deadline?
- Apr 5, 2027.
- Who is eligible to apply?
- Small businesses.
- Which locations are eligible?
- US.
- What can the funding be used for?
- feasibility studies, research and development, develop a commercial product, as classified by the source.
- Is matching funding required?
- No. The source states that no matching funds are required.
AI summary of the source text
Optional. Every core field on this record is already above, free and complete.
AI summary of the source text
Studio reads this record’s stored eligibility and materials text and breaks it into separate points, each quoting the exact words it came from. It never writes application prose, never guesses at a field the source did not state, and never estimates anyone’s chances.
Included with Studio
Sign inWhat else is open
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)Closes Nov 13, 2026Awards up to $1,050,000
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)Closes Nov 13, 2026Awards up to $350,000
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)Closes Nov 17, 2026Awards Not stated
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)Closes Nov 19, 2026Awards Not stated
- Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)Closes Dec 3, 2026Awards Not stated
- Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)Closes Jan 7, 2027Awards up to $250,000
A listing names the programme; a notice names one round of it. These are other rounds open now, not other years of this one.
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)Closes Nov 13, 2026Awards up to $1,050,000
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)Closes Nov 13, 2026Awards up to $350,000
- Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)Closes Nov 17, 2026Awards Not stated
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)Closes Nov 19, 2026Awards Not stated
- Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)Closes Dec 3, 2026Awards Not stated
- Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional)Closes Jan 7, 2027Awards up to $250,000
The official page governs. If the source and this record disagree, the source is correct — programmes change their terms between our checks, so confirm every figure above before you apply.